Walgreens Boots Alliance Competitive Strategy & SWOT Analysis
Despite its current financial difficulties, Walgreens Boots Alliance retains several genuine competitive advantages that represent the foundation upon which any successful turnaround must be built. Network Scale and Geographic Density With more than 8,700 U.S. Store locations even after planned closures, Walgreens maintains a physical retail network that no online pharmacy can replicate. Approximately 78 percent of Americans live within five miles of a Walgreens pharmacy — a statistic that reflects decades of deliberate real estate strategy. This proximity advantage is most valuable for urgent prescription needs, same-day medication access, and in-person pharmacist consultation, services that delivery-focused competitors cannot match for patients who need their medication immediately. Pharmacist Workforce and Clinical Credibility Walgreens employs approximately 25,000 pharmacists in the United States, representing one of the largest single-employer pharmacist workforces in the country. This clinical workforce is a genuine asset. State-level scope-of-practice expansions are increasingly allowing pharmacists to prescribe certain medications, administer vaccinations, and provide clinical testing services — capabilities that Walgreens pharmacists are already exercising and that differentiate the company from pure-play online competitors. Vaccination Infrastructure During the COVID-19 pandemic, Walgreens administered more than 60 million COVID-19 vaccine doses, establishing the company as a trusted public health partner with governments at the federal, state, and local levels. This vaccination infrastructure — including trained staff, cold storage capabilities, scheduling systems, and public trust — represents a durable advantage in immunization services broadly. Boots No7 and Own-Brand Portfolio Through the Boots brand, WBA controls one of the most recognized pharmacy-adjacent beauty brands in the world. The No7 skincare line generates significant revenue and carries margins far superior to generic merchandise, demonstrating the value-creation potential of proprietary product development within the pharmacy retail context. Loyalty Program Scale The combined myWalgreens program in the U.S. And the Boots Advantage Card in the UK together enroll more than 120 million members, creating a proprietary first-party data asset of substantial value for targeted marketing, health interventions, and potential data partnership monetization.
SWOT Analysis: Walgreens Boots Alliance
Market Position & Competitive Landscape
The competitive landscape in which Walgreens Boots Alliance operates has undergone a seismic transformation over the past decade, and the company now finds itself fighting on multiple fronts against competitors with fundamentally different business models and, in some cases, far deeper resources. CVS Health: The Integrated Competitor The most formidable direct competitor is CVS Health, which has executed a strategic transformation that Walgreens has attempted but not matched. When CVS acquired Aetna in 2018 for 69 billion dollars, it was not simply buying an insurance company — it was acquiring the ability to align incentives across the entire patient journey, from coverage design to prescription fulfillment to clinical care delivery. CVS Caremark, the company's pharmacy benefit management arm, controls access to enormous prescription volume and allows CVS to negotiate from a position of vertical integration that pure-play pharmacy retailers cannot match. CVS Health's MinuteClinic urgent care model, with more than 1,100 locations, has also proven more financially sustainable than Walgreens' VillageMD experiment, partly because it focuses on acute episodic care rather than the more capital-intensive model of ongoing primary care practice management. By fiscal year 2024, CVS Health reported revenues of approximately 372 billion dollars — more than twice Walgreens' consolidated revenue — reflecting the enormous scale advantage that vertical integration delivers. CVS has approximately 9,900 U.S. Pharmacy locations compared to Walgreens' roughly 8,700 post-closure footprint, and CVS pharmacies typically generate higher revenues per location due to more favorable PBM contract terms that CVS negotiates with itself through Caremark. Amazon Pharmacy: The Digital Disruptor Amazon's entry into pharmacy is perhaps the existential threat that Walgreens executives have found most difficult to address. Launched formally in November 2020, Amazon Pharmacy offers prescription delivery to Prime members at prices that frequently undercut what patients pay at physical pharmacy locations, particularly for generic medications. Amazon's RxPass subscription, launched in early 2023, allows Prime members to access more than 50 generic medications for a flat six-dollar monthly fee — a pricing model so aggressive it directly attacks the economics of generic prescription fills at physical pharmacies. Amazon's structural advantages in pharmacy are formidable: its logistics infrastructure enables next-day or two-day delivery of most prescriptions across the continental United States; its Prime membership base of more than 200 million subscribers globally provides an enormous captive audience; its technology platform enables seamless digital prescription management; and its capital base allows it to absorb losses in pharmacy while building market share. The acquisition of PillPack in 2018 for approximately one billion dollars gave Amazon the pharmacy licensing, fulfillment technology, and multi-dose packaging capability to serve patients with complex medication regimens, a market Walgreens had considered its own. Costco and Walmart: The Value Competitors For customers without comprehensive pharmacy insurance coverage, Costco and Walmart have long offered aggressively priced generic prescriptions that make the Walgreens retail pharmacy appear expensive by comparison. Walmart's four-dollar generic medication program, launched in 2006, permanently altered consumer price expectations for generic drugs and eroded the price premium that chain pharmacies had historically enjoyed. Costco's pharmacy operations, available even to non-members for prescription purchases, further commoditize the generic drug dispensing business. Dollar General and Dollar Tree: The Front-of-Store Threat While not pharmacy competitors, Dollar General and Dollar Tree have systematically captured the value-oriented consumer who once browsed the front-of-store aisles at Walgreens for household consumables, seasonal merchandise, and snacks. With more than 35,000 combined locations — many in the same rural and suburban markets where Walgreens is concentrated — these dollar store chains offer convenience merchandise at prices that Walgreens' cost structure cannot match. The result has been a secular decline in front-of-store traffic and transaction volumes that has compounded the pharmacy revenue pressures. Walgreens' Competitive Response Faced with these converging competitive pressures, Walgreens' competitive strategy under Tim Wentworth has shifted from offense to defense and rationalization. The company is attempting to compete on the basis of pharmacist expertise, physical accessibility, and the unique trust relationship between patients and their local pharmacist — advantages that are real but have proven difficult to monetize at scale in the current reimbursement environment. The company is also working to accelerate its own digital pharmacy capabilities, having launched Walgreens Pharmacy online prescription management services that allow patients to manage refills, request transfers, and access digital pharmacist consultations.